Table 5—

Changes in functional class, haemodynamics and six-minute walk test (6MWT) characteristics observed after 5±2 months of treatment in idiopathic and nonidiopathic pulmonary arterial hypertension (PAH)

	Idiopathic PAH^#		Nonidiopathic PAH^¶
	Baseline	Post-treatment	Baseline	Post-treatment
Haemodynamics
mRAP mmHg	7±4	8±5	10±7	7±4**
mPAP mmHg	58±13	52±15**	49±13	45±9
PAOP mmHg	9±3	8±3	8±4	7±3
CO L·min⁻¹	4.69±1.16	5.23±1.23**	4.76±1.58	5.66±1.65**
SV mL	59±18	67±21**	57±23	65±21**
PVR mmHg·min·L⁻¹	11.3±4.0	9.1±4.1**	10.0±5.2	7.3±3.1**
S_v,O₂ %	64±8	65±8	60±13	64±9
HR beats·min⁻¹	81±12	80±12	86±14	88±11
6MWT characteristics
Distance	429±92	456±105*	375±92	420±76**
S_P,O₂,rest %	95±3	96±2	94±3	94±4
S_P,O₂,min %	90±5	92±4**	87±6	88±7
ΔS_P,O₂ %	−5±4	−3±3*	−8±4	−7±4
HR_rest beats·min⁻¹	86±15	83±11	92±14	93±9
HR_peak beats·min⁻¹	120±18	120±16	121±15	120±9
ΔHR beats·min⁻¹	34±16	37±17	29±14	27±9
Borg scale	3.5±1.7	2.6±1.6**	3.6±1.2	2.5±1.1**

Data are expressed as mean±sd. Only statistically significant relationships are noted. In idiopathic PAH, treatments included oral bosentan (n = 28), intravenous epoprostenol (n = 9) and both (n = 3). In nonidiopathic PAH, treatments included oral bosentan (n = 10), intravenous epoprostenol (n = 5) and inhaled iloprost (n = 2). mRAP: mean right atrial pressure; mPAP: mean pulmonary arterial pressure; PAOP: pulmonary arterial occlusion pressure; CO: cardiac output; SV: stroke volume; PVR: pulmonary vascular resistance; S_v,O₂: mixed venous oxygen saturation; HR: heart rate; S_P,O₂,rest: peripheral oxygen saturation measured at rest; S_P,O₂,min: minimal S_P,O₂ measured during 6MWT; ΔS_P,O₂: desaturation measured during the 6MWT (S_P,O₂,min–S_P,O₂,rest); HR_rest: heart rate measured at rest; HR_peak: peak heart rate measured during the 6MWT; ΔHR: chronotropic response (HR_peak–HR_rest). ^#: n = 40; ^¶: n = 17. *: p<0.05; **: p<0.01.